Alzheimer’s Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

This report covers the 68 geographical markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033.
GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Aβmonoclonal antibodies (mAbs) across the 8MM. The US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and $915.2 million (38.8%), respectively. The smallest market is France, contributing only 1.1% to total global sales, due to the lower AD prevalent population in the country, as well as the lack of reimbursement of the current AD symptomatic therapies resulting in lower treatment rates in France.
By the end of the forecast period in 2033, GlobalData projects AD sales to rise to $17.0 billion in the 8MM, at a compound annual growth rate (CAGR) of 21.8%.
Across the 68 markets, sales in the AD market were $3.1 billion in 2023, growing to $20.0 billion in 2033. The eight major markets (US, France, Germany, Italy, Spain, UK, Japan and China) represent approximately 75.2% and 85.2% of 68-market sales in 2023 and 2033, respectively.

Scope

Overview of Alzheimer’s Disease, including epidemiology, symptoms, diagnosis, and disease management.

Annualized Alzheimer’s Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global Alzheimer’s Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 8MM Alzheimer’s Disease therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM Alzheimer’s Disease therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Eli Lilly and Co
Otsuka Pharmaceutical Co Ltd
Novartis AG
Biogen Inc
Eisai Co Ltd
Suven Life Sciences Ltd
Towa Pharmaceutical Co Ltd
AB Science SA
H. Lundbeck AS
Neurimmune Holding AG
Annovis Bio Inc
Teikoku Seiyaku Co Ltd
AbbVie Inc
BioVie Inc
Alzheon Inc
Axsome Therapeutics Inc
TauRx Pharmaceuticals Ltd
Anavex Life Sciences Corp
Shanghai Green Valley Pharmaceutical Co Ltd
Johnson & Johnson
Corium LLC
Bristol-Myers Squibb Co
Ono Pharmaceutical Co Ltd
Novo Nordisk AS
Daiichi Sankyo Co Ltd
AriBio Co Ltd
Luye Pharma Group Ltd
BioXcel Therapeutics Inc
AlphaCognition Inc
Biomed Industries Inc
Cerecin Inc

Table of Contents

About GlobalData

List of Contents

List of Tables

List of Figures

1 Executive Summary

1.1 Overview

1.2 68M summary statistics

1.3 Key 8MM events driving the 68M forecast extrapolation

2 Appendix

2.1 Abbreviations

2.2 Methodology

2.2.1 Patient-based forecast methodology

2.2.2 68M forecast extrapolation methodology.

2.3 Primary research – key opinion leaders interviewed for this report.

2.4 Primary research – prescriber survey

2.5 About the authors

2.5.1 Analyst

2.5.2 Therapy area directors

2.5.3 Epidemiologist

2.5.4 Epidemiology reviewers

2.5.5 Vice President of Disease Intelligence and Epidemiology

2.5.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

Contact Us

Table

Table 1: MCI and AD: Key metrics in the 8MM

Table 2: Three-stage classification of AD

Table 3: The seven-stage Reisburg Scale of AD

Table 4: Proposed NIA-AA staging classification for preclinical AD

Table 5: Common symptoms of AD

Table 6: Risk factors and comorbidities for AD

Table 7: Summary of NINCDS-ARDA diagnostic criteria for AD

Table 8: Most prescribed drugs for AD by class in the 8MM

Table 9: Most prescribed off-label drug classes for secondary AD symptoms by class in the 8MM

Table 10: Treatment Guidelines for AD

Table 11: AD market – global drivers and barriers, 2020–30

Table 12: Key events impacting sales for AD in the US, 2020–30

Table 13: AD market – drivers and barriers in the US, 2020–30

Table 14: Key events impacting sales for AD in the 5EU, 2020–30

Table 15: AD market – drivers and barriers in the 5EU, 2020–30

Table 16: Key events impacting sales for AD in Japan, 2020–30

Table 17: AD market – drivers and barriers in Japan, 2020–30

Table 18: Key events impacting sales for AD in China, 2020–30

Table 19: AD market – drivers and barriers in China, 2020–30

Table 20: AD clinical development pipeline by drug class

Table 21: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for AD in 2020 and 2030

Figure 2: Analysis of the company portfolio gap in AD during the forecast period

Figure 3: Competitive assessment of the injectable DMTs benchmarked against Aduhelm

Figure 4: AD biomarker tests by [athophysiology

Figure 5: 8MM, total prevalence of AD (%), men and women, ages ≥60 years, 2020

Figure 6: 8MM, total prevalence of MCI (%), men and women, ages ≥60 years, 2020

Figure 7: 8MM, sources used and not used to forecast the total prevalent cases of AD based on the DSM-IV and clinical criteria

Figure 8: 8MM, sources used and not used to forecast the total prevalent cases of MCI

Figure 9: 8MM, sources used to forecast the total prevalent cases of AD by severity

Figure 10: 8MM, total prevalent cases of AD, both sexes, ages ≥60 years, 2020

Figure 11: 8MM total prevalent cases of AD, by sex, ages ≥60 years, N, 2020

Figure 12: 8MM, total prevalent cases of AD, by age, both sexes, N, 2020

Figure 13: 8MM, total prevalent cases of AD, by severity, both sexes, ages ≥60 years, N, 2020

Figure 14: 8MM, diagnosed prevalent cases of AD, both sexes, ages ≥60 years, N, 2020

Figure 15: 8MM, diagnosed prevalent cases of AD, by sex, ages ≥60 years, N, 2020

Figure 16: 8MM, diagnosed prevalent cases of AD by age, both sexes, N, 2020

Figure 17: 8MM, diagnosed prevalent cases of AD by severity, both sexes, ages ≥60 years, N, 2020

Figure 18: 8MM, total prevalent cases of MCI, both sexes, ages ≥60 years

Figure 19: 8MM, total prevalent cases of MCI, by sex, ages ≥60 years, N, 2020

Figure 20: 8MM, total prevalent cases of MCI, by age, both sexes, N, 2020

Figure 21: 8MM, diagnosed prevalent cases of MCI, both sexes, ages ≥60 years

Figure 22: 8MM, diagnosed prevalent cases in MCI, by sex, ages ≥60 years, N, 2020

Figure 23: 8MM, diagnosed prevalent cases in MCI, by age, both sexes, N, 2020

Figure 24: 8MM, treatment algorithm for AD

Figure 25: 8MM, disease management timeline for AD

Figure 26: Unmet needs and opportunities in AD

Figure 27: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for AD in the 8MM during the forecast period

Figure 28: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for agitation associated with AD in the 8MM during the forecast period

Figure 29: Competitive assessment of the injectable pipeline DMTs benchmarked against Aduhelm (aducanumab)

Figure 30: Competitive assessment of the oral pipeline DMTs benchmarked against oral generic donepezil

Figure 31: Competitive assessment of the pipeline agents for agitation associated with AD benchmarked against Risperdal (risperidone)

Figure 32: Competitive assessment of the other symptomatic therapies benchmarked against donepezil (oral)

Figure 33: Analysis of the company portfolio gap in AD during the forecast period

Figure 34: Global (8MM) sales forecast by country for AD in 2020 and 2030

Figure 35: Global (8MM) sales forecast by class for AD in 2020 and 2030

Figure 36: Sales forecast by class for AD in the US in 2020 and 2030

Figure 37: Sales forecast by class for AD in the 5EU in 2020 and 2030

Figure 38: Sales forecast by class for AD in Japan in 2020 and 2030

Figure 39: Sales forecast by class for AD in China in 2020 and 2030

Alzheimer’s Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Alzheimer’s Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alzheimer’s Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 in real time.

  • Access a live Alzheimer’s Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.